Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31 2023 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today reported the
grant of 93,950 restricted stock units of Atara’s common stock to
three newly hired employees. These awards were approved by the
Compensation Committee of Atara’s Board of Directors and granted
under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a
grant date of April 3, 2023, as an inducement material to the new
employees entering into employment with Atara, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers, and
autoimmune disease. With our lead program receiving marketing
authorization in Europe, Atara is the most advanced allogeneic
T-cell immunotherapy company and intends to rapidly deliver
off-the-shelf treatments to patients with high unmet medical need.
Our platform leverages the unique biology of EBV T cells and has
the capability to treat a wide range of EBV-associated diseases, or
other serious diseases through incorporation of engineered CARs
(chimeric antigen receptors) or TCRs (T-cell receptors). Atara is
applying this one platform, which does not require TCR or HLA gene
editing, to create a robust pipeline including: tab-cel for
Epstein-Barr virus positive post-transplant lymphoproliferative
disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell
immunotherapy targeting EBV antigens as a potential treatment for
multiple sclerosis; and multiple next-generation chimeric antigen
receptor T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in Southern California. For
additional information about the company, please visit atarabio.com
and follow us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230329005956/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com Media Alex Chapman
805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Aug 2023 to Aug 2024